about
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Renal tumors: diagnostic and prognostic biomarkersElevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapyEZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal originImproving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network.Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.Solitary fibrous tumour of the prostate identified on needle biopsy.Cystic lesions of the prostate gland: an ultrasound classification with pathological correlation.Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor.Evidence for common clonal origin of multifocal lung cancers.Clonality and TP53 mutation analysis of focal nodular hyperplasia of the liver.Clonal origin of multifocal hepatocellular carcinoma.The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.Mixed epithelial and stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation.The origins of urothelial carcinoma.Utility of whole slide imaging and virtual microscopy in prostate pathology.Laser-assisted microdissection in translational research: theory, technical considerations, and future applications.Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis.The role of focal therapy in the management of localised prostate cancer: a systematic review.2004 WHO classification of the renal tumors of the adults.[Prostate biopsy: characteristics of the histological sample].Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation.Staging of prostate cancer.Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.Evaluation of prognostic factors in radical prostatectomy specimens with cancer.Intratubular germ cell neoplasia of the testis: testicular intraepithelial neoplasia.Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.Staging and reporting of urothelial carcinoma of the urinary bladder.Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance.Prostate changes related to therapy: with special reference to hormone therapy.Molecular techniques and prostate cancer diagnostic.Handling and pathology reporting of radical prostatectomy specimens.Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention.Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis.Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors.Does finasteride alter the pathology of the prostate and cancer grading?Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry.Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group.
P50
Q26740601-54DB0397-E94C-48E9-A3E9-FFAED7068C43Q26860500-D423922C-3456-4A16-8C08-DAF82A0D9A95Q27851813-8DFE2374-3BE9-423F-9DED-556AA5285BA5Q30538848-B2C406E7-45CE-4894-87D2-17E5F1032C64Q31005436-F50EC09D-242D-49B4-BC82-D7848D709CC8Q31082782-BFAC81B4-6E21-4B59-AC68-22370C8D654EQ33369059-90AF914A-F333-4594-81B0-3A0C0BDB2B94Q33374194-AF65B7C9-50FB-4D1E-8907-A11B93AD5E64Q33383552-DE7110D7-4081-4D95-980E-C71CBB1D7B5CQ33394085-15A312C0-3FA5-473E-A7CF-B04487B7C4B0Q33416718-A12BD331-E62B-4381-890C-77FB4E1670ABQ33427737-56E4A88D-ABF8-4FF8-9175-B7D48119C956Q33605576-6EA8301F-C992-4C22-8FAE-C2E9C8CE63F4Q33610269-77065C63-F9DA-483A-A930-A604F3D2FE6FQ33874785-F5E48934-EAF9-473D-9AF0-C7EB2D7A0671Q33960146-2B819FCC-AE62-4317-9118-C67569CCF210Q34121078-B043427D-7E4E-42EA-9A70-1E63ECC9EE62Q34201467-35B7D5A8-7360-4843-99E1-8DC9EAD44934Q34229147-124BE994-B5A2-4093-95FB-88C2752B446BQ34258858-1C2DBA63-432B-4B1E-87F4-77C1B9B1A65DQ34266167-8430F6D1-7284-41B2-83DA-9B9C046ED590Q34488979-623AEF37-DB45-4AFE-8231-E655CC7DA622Q34564017-77B262CF-E022-4F1B-97FA-18EE3B5D2D7BQ34593477-922AB53D-9BCD-4EC3-9189-FA4B6B4C587DQ34634756-67A16E8C-4816-421E-AED5-BD8E1139D27DQ34634850-0380E816-5679-4E06-B1EA-3A3DAFF423B7Q34674929-3E385EE4-AA61-4BBB-AA4D-6BD5D658607DQ34696416-75207D5E-7E14-4D95-83FC-DDE32CD599AEQ34723833-F506E9FD-6F9D-49B6-9D0D-A0CFD6F3AC11Q34984796-B13F8C9E-9188-4E1F-876B-C42986D2528DQ35088833-EF824882-D35B-4E1A-ACB6-41B0CCC1EAE4Q35344149-1415DA3D-5EEE-45A8-A16D-F98471D8E2C2Q35538323-2191B57E-E488-4B70-90E6-D65285F5A242Q35595805-3A36C75E-27E0-4160-AF78-D8AE619BB448Q35602389-0C1DCF34-E52B-4C6D-BBE0-A080F90354DFQ35704227-CCF37C11-469B-4EED-981E-6D11D54481FAQ35715762-824E6B94-5630-4233-BF67-629970B006D6Q35741384-C787983F-1E1D-48C8-B73A-F190004A5245Q35770488-6EBA9655-7561-4D5D-B515-7A1D2400F95FQ35797243-797A0BF0-BC3D-44D5-A425-A5C88ACEB2FF
P50
name
Rodolfo Montironi
@en
Rodolfo Montironi
@nl
type
label
Rodolfo Montironi
@en
Rodolfo Montironi
@nl
prefLabel
Rodolfo Montironi
@en
Rodolfo Montironi
@nl